Chennai:Global biopharmaceutical giantAstraZenecahas announced fresh investments of Rs 176 crore in India, reinforcing its commitment to healthcare innovation and technology. The announcement was made during the Tamil Nadu government’s “TN Rising” campaign in London,coinciding withChief Minister M.K. Stalin’s visit to the United Kingdom. The investment will expand the Global Innovation and Technology Centre’s infrastructure and capabilities to strengthen its position as a leader in healthcare innovation both globally and in India, a company statement said here on Saturday. It is the third investment by AstraZeneca after it announced investments of Rs 166 crore in June towards the establishment of a state-of-the-art Global Hub in Bengaluru. Read also:AstraZeneca expands Global Hub in Bangalore with Rs 166 crore investment In July 2024, AstraZeneca announced investments of Rs 250 crore towards expanding the Global Innovation and Technology Centre in Chennai. Read also:AstraZeneca Imfinzi application granted priority review by USFDA for resectable early stage gastric, gastroesophageal junction cancers
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!